DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
+12.7%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$2.14B
AUM Growth
+$2.14B
(-9%)
Cap. Flow
-$349M
Cap. Flow
% of AUM
-16.32%
Top 10 Holdings %
Top 10 Hldgs %
51.57%
Holding
70
New
11
Increased
14
Reduced
13
Closed
12
Top Buys
| 1 |
Guardant Health
GH
|
$53.7M |
| 2 |
Editas Medicine
EDIT
|
$28.4M |
| 3 |
ANI Pharmaceuticals
ANIP
|
$27.7M |
| 4 |
Axsome Therapeutics
AXSM
|
$27.6M |
| 5 |
Zura Bio
ZURA
|
$20.7M |
Top Sells
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Jazz Pharmaceuticals
JAZZ
$7.75B
| $155M | 7.17% | 1,250,000 +50,000 | +4% | +$6.2M |
|
2
Insmed
INSM
$28.8B
| $137M | 6.35% | 6,500,000 | – | – |
|
3
Ionis Pharmaceuticals
IONS
$6.79B
| $116M | 5.38% | 2,834,069 | – | – |
|
4
Travere Therapeutics
TVTX
$1.56B
| $113M | 5.24% | 7,370,000 +1,222,732 | +20% | +$18.8M |
|
5
Structure Therapeutics
GPCR
$1.11B
| $110M | 5.09% | 2,646,782 | – | – |
|
6
Immunovant
IMVT
$2.56B
| $103M | 4.76% | 5,421,330 -2,011,387 | -27% | -$38.2M |
|
|
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $98M | 4.54% | 1,548,252 -151,748 | -9% | -$9.61M |
|
8
Alkermes
ALKS
$4.78B
| $93.9M | 4.35% | 3,000,000 | – | – |
|
|
SWTX
9
DELISTED
SpringWorks Therapeutics
SWTX
| $93M | 4.3% | 3,546,435 +446,435 | +14% | +$11.7M |
|
10
Dynavax Technologies
DVAX
$1.19B
| $84.7M | 3.92% | 6,557,816 +207,816 | +3% | +$2.68M |
|
11
Geron
GERN
$893M
| $77.6M | 3.59% | 24,170,966 -2,696,513 | -10% | -$8.66M |
|
12
Pliant Therapeutics
PLRX
$101M
| $73.4M | 3.4% | 4,050,000 +627,943 | +18% | +$11.4M |
|
|
BCYC
13
Bicycle Therapeutics
BCYC
$511M
| $71.9M | 3.33% | 2,819,045 | – | – |
|
|
VRNA
14
Verona Pharma
VRNA
$9.16B
| $67.4M | 3.12% | 3,187,415 | – | – |
|
|
15
Guardant Health
GH
$8.41B
| $53.7M | 2.49% | +1,500,000 | New | +$53.7M |
|
16
4D Molecular Therapeutics
FDMT
$288M
| $50.2M | 2.32% | 2,778,107 +500,000 | +22% | +$9.04M |
|
|
AGEN
17
Agenus
AGEN
$133M
| $48M | 2.22% | 30,000,000 | – | – |
|
18
Beam Therapeutics
BEAM
$1.66B
| $42.1M | 1.95% | 1,317,316 +67,316 | +5% | +$2.15M |
|
|
AUTL
19
Autolus Therapeutics
AUTL
$399M
| $35.7M | 1.65% | 15,000,000 | – | – |
|
20
Intellia Therapeutics
NTLA
$1.22B
| $34.1M | 1.58% | 835,446 +130,913 | +19% | +$5.34M |
|
21
Viridian Therapeutics
VRDN
$1.5B
| $30.4M | 1.41% | 1,279,502 +49,243 | +4% | +$1.17M |
|
22
Nurix Therapeutics
NRIX
$714M
| $29.9M | 1.39% | 2,997,830 | – | – |
|
23
Repare Therapeutics
RPTX
$71.7M
| $28.9M | 1.34% | 2,727,606 | – | – |
|
|
24
Editas Medicine
EDIT
$231M
| $28.4M | 1.32% | +3,453,744 | New | +$28.4M |
|
25
Dyne Therapeutics
DYN
$1.92B
| $28.1M | 1.3% | 2,499,912 +165,279 | +7% | +$1.86M |
|